Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEmma SmithAWAlan F. WilliamsMTMichael Tolstorukov

Discussion

Loading...

Member takes

Overview

Venetoclax and inotuzumab ozogamicin treat acute lymphoblastic leukemia, revealing predictors of resistance and minimal residual disease.

Key Points

  • Complete remission showed high rates, with 21 of 22 patients evaluable, and primary predictors of minimal residual disease assessed by clonoSEQ.
  • Baseline apoptotic priming by BH3 profiling correlated with cycle 2 minimal residual disease positivity, indicating treatment resistance.
  • Observational analysis evaluated bone marrow specimens, employing immunoglobulin sequencing to measure minimal residual disease and mutation profiling.
  • Findings suggest reduced apoptotic priming may help predict outcomes, while various resistance mechanisms were noted in relapsed patients.

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0dehttps://doi.org/10.1182/blood-2025-329
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial2025 · 2 citations
  2. 2Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)2025 · 1 citations
  3. 3Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study2025
  4. 4Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia2025
  5. 5A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group2025